Patanjali Ayurveda slams USFDA report on differential labelling
In a report, the US food and drugs regulator has claimed that labels on two Patanjali products sold in India have additional medicinal and dietary claims compared to the products manufactured for exports.
Baba Ramdev's Patanjali Ayurveda has slammed the US Food and Drug Administration for its report raising concerns over differential labelling by the company.
In a report, the US food and drugs regulator has claimed that labels on two Patanjali products sold in India have additional medicinal and dietary claims compared to the products manufactured for exports.
The report is pertaining to the 'bel' and 'gulab sharbat' bottles that the company manufactures. The two products are manufactured at two separate plants, one for domestic use and one for export purpose.
Patanjali sees this is as a gross misrepresentation to defame the company. The company said it was following regulatory norms as far as packaging and labelling of its products are concerned and is in complete compliance with regulations of the countries that it exports to. The company also says it has not received any notice as of now from the USFDA on any of the accusations made.
First Published: Jul 23, 2019 8:39 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Lok Sabha Election 2024 Phase 5: 24% voter turnout recorded till 11 am, highest in Bengal at 33%
May 20, 2024 10:30 AM
Lok Sabha Election 2024: Is it mandatory for employers to give paid holiday on voting day? | Explained
May 20, 2024 10:07 AM
Lok Sabha Elections 2024 | How critical is Phase-5 for both NDA and I.N.D.I.A
May 20, 2024 7:30 AM